Imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators have been described in a UCB SA patent and are reported to be potentially useful for the treatment of inflammatory disorders and autoimmune diseases.
Ono Pharmaceutical Co. Ltd. inked deals with Shattuck Labs Inc. and Numab Therapeutics AG aimed at bolstering its pipeline in oncology and autoimmune and inflammatory diseases. Ono struck a drug discovery collaboration and option agreement with Shattuck Labs to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases. It also signed a global research, development and commercialization deal with Numab for its NM-49, a multispecific antibody designed to activate tumor-associated macrophage phagocytosis for treating cancers.
Receptor-interacting protein kinase 1 (RIPK1) regulates cell cycle and counteracts necroptosis, and is hence considered a target to watch in necroptosis-related conditions such as cancer or inflammatory diseases. Researchers from Sichuan University have reported on the discovery and structural optimization of a novel series of selective RIPK1 inhibitors intended for use in the treatment of inflammatory disorders.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration and option agreement with Shattuck Labs Inc. to generate bifunctional fusion proteins.
NLRP3 inflammasome inhibitors have been disclosed in a Kodiak Sciences Inc. patent and described as useful for the treatment of atherosclerosis, gout, rheumatoid arthritis, inflammatory bowel, Alzheimer’s, Parkinson diseases, multiple sclerosis and glaucoma.
Graviton Bioscience Corp. has announced a strategic investment from Sanofi SA. Under the agreement, Sanofi receives a right of first negotiation to license compounds across various indications, including immunological and metabolic syndrome indications.
Halia Therapeutics Inc. has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing. The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead asset, a selective and orally bioavailable first-in-class NLRP3/NEK7 inflammasome inhibitor.
Synthekine Inc. has established a worldwide collaboration with Sanofi SA to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.
It has been previously demonstrated that genetic variability of thioredoxin reductase 1 (TXNRD1) is associated with aging and age-associated phenotypes. Researchers from MD Anderson Cancer Center have now conducted work to assess the role of TXNRD1 in regulating tissue aging.
RSS
